Profile data is unavailable for this security.
About the company
Camurus AB is a Sweden-based research and development based pharmaceutical and biotechnology company with a focus on the development and marketing of specialty medicines, providing patients suffering from severe and chronic disease, such as opioid dependence, pain, cancer, and endocrine diseases. The Company has a diversified research portfolio, which includes products in clinical trials. The Company’s products are based on FluidCrystal formulation technology. FluidCrystal is Company's patent-protected technology platform. Camurus AB is the parent company of the Group, which comprises of legal entities, namely: Camurus Inc, Cubosome Inc, Development AB, Camurus GmbH, Camurus Ltd, Camurus Oy, Camurus AS, Camurus SAS, Camurus Pty Ltd, Camurus S.L, Camurus ApS, Camurus BV and Camurus Austria GmbH.
- Revenue in SEK (TTM)1.72bn
- Net income in SEK431.44m
- Incorporated2004
- Employees213.00
- LocationCamurus ABIdeongatan 1ALUND 223 62SwedenSWE
- Phone+46 462865730
- Fax+46 462865739
- Websitehttps://www.camurus.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Calliditas Therapeutics AB | 1.21bn | -466.18m | 6.67bn | 195.00 | -- | 17.95 | -- | 5.53 | -8.69 | -8.69 | 22.49 | 6.24 | 0.6332 | 5.02 | 9.30 | 6,189,175.00 | -24.46 | -26.46 | -30.27 | -30.27 | 94.99 | -- | -38.63 | -76.59 | 3.08 | -4.44 | 0.7427 | -- | 50.32 | -- | -13.08 | -- | -- | -- |
Surgical Science Sweden AB | 882.85m | 233.97m | 7.63bn | 260.00 | 32.58 | 1.76 | 26.34 | 8.64 | 4.59 | 4.59 | 17.32 | 85.16 | 0.1888 | 1.87 | 6.15 | 3,395,585.00 | 5.00 | 4.49 | 5.31 | 4.78 | 69.42 | 70.06 | 26.50 | 23.75 | 3.56 | -- | 0.00 | 0.00 | 10.01 | 68.14 | 24.47 | -- | 38.57 | -- |
Swedencare AB (publ) | 2.41bn | 71.50m | 8.43bn | 552.00 | 117.88 | 1.09 | 21.98 | 3.49 | 0.4505 | 0.4505 | 15.21 | 48.80 | 0.2412 | 2.35 | 9.52 | 4,966,461.00 | 0.7144 | 1.38 | 0.7361 | 1.43 | 55.64 | 55.34 | 2.96 | 5.10 | 1.82 | 2.21 | 0.1746 | 45.33 | 27.48 | 88.16 | -37.96 | 20.24 | 30.90 | -- |
Gubra A/S | 321.43m | -69.81m | 8.66bn | 219.00 | -- | 11.48 | -- | 26.96 | -2.91 | -2.91 | 13.51 | 29.44 | -- | -- | -- | 936,095.90 | -- | -- | -- | -- | 56.06 | -- | -21.72 | -- | -- | -- | 0.1296 | -- | 2.82 | -- | -1,133.04 | -- | -- | -- |
BioGaia AB | 1.30bn | 371.25m | 12.16bn | 211.00 | 34.00 | 5.82 | 30.73 | 9.35 | 3.68 | 3.68 | 12.88 | 21.47 | 0.5414 | -- | -- | 6,192,767.00 | 15.46 | 15.47 | 16.82 | 16.93 | 73.32 | 73.30 | 28.55 | 27.70 | -- | -- | 0.00 | 104.42 | 17.44 | 11.81 | -2.25 | 11.20 | 29.27 | 28.10 |
AddLife AB | 9.80bn | 79.00m | 12.66bn | 2.29k | 165.66 | 2.53 | 12.43 | 1.29 | 0.6483 | 0.6483 | 80.41 | 42.38 | 0.7393 | 3.62 | 5.53 | 4,258,149.00 | 0.6112 | 5.31 | 0.9299 | 8.83 | 37.16 | 36.89 | 0.8267 | 5.79 | 0.4778 | 1.48 | 0.5173 | 31.73 | 6.62 | 31.30 | -60.42 | 8.00 | 44.43 | -1.89 |
BioArctic AB | 616.00m | 229.25m | 14.43bn | 88.00 | 75.60 | 16.46 | 58.27 | 23.43 | 2.58 | 2.58 | 6.97 | 11.85 | 0.6026 | -- | -- | 6,999,943.00 | 22.43 | 2.24 | 24.80 | 2.56 | 91.73 | 86.52 | 37.22 | 9.76 | -- | -- | 0.0047 | 0.00 | 169.83 | -2.91 | 2,150.71 | -9.69 | 11.83 | -- |
Bonesupport Holding AB | 655.75m | 266.56m | 15.18bn | 121.00 | 57.11 | 26.82 | 54.79 | 23.15 | 4.05 | 4.05 | 9.96 | 8.61 | 1.19 | 0.657 | 6.36 | 6,245,276.00 | 48.22 | -9.08 | 61.41 | -11.28 | 92.01 | 90.25 | 40.65 | -11.65 | 2.42 | -- | 0.0282 | -- | 79.76 | 43.65 | 459.44 | -- | 18.39 | -- |
Bavarian Nordic A/S | 10.41bn | 1.54bn | 19.95bn | 1.38k | 12.67 | 1.25 | 8.07 | 1.92 | 12.86 | 12.86 | 86.59 | 130.35 | 0.4956 | 1.74 | 9.32 | 4,816,359.00 | 7.35 | 1.21 | 8.92 | 1.48 | 60.90 | 53.72 | 14.82 | 4.06 | 1.03 | -- | 0.0427 | 0.00 | 124.14 | 69.78 | 524.66 | -- | 35.76 | -- |
Vitrolife AB | 3.50bn | -3.84bn | 24.14bn | 1.13k | -- | 1.82 | -- | 6.90 | -28.33 | -28.33 | 25.84 | 97.73 | 0.1859 | 3.76 | 6.54 | 3,242,818.00 | -20.38 | -4.57 | -21.03 | -4.78 | 56.39 | 58.38 | -109.60 | -21.89 | 2.98 | -30.31 | 0.1353 | -- | 8.60 | 24.99 | -1,077.41 | -- | -7.95 | 3.30 |
Camurus AB | 1.72bn | 431.44m | 30.83bn | 213.00 | 71.38 | 19.93 | 69.21 | 17.96 | 7.49 | 7.49 | 30.11 | 26.84 | 1.07 | 1.17 | 7.29 | 8,060,329.00 | 26.85 | -1.13 | 33.67 | -1.41 | 92.87 | 90.05 | 25.13 | -1.63 | 4.13 | -- | 0.0162 | -- | 79.52 | 103.39 | 676.63 | -- | 16.29 | -- |
Holder | Shares | % Held |
---|---|---|
Fj�rde AP-fondenas of 30 Nov 2023 | 2.49m | 4.32% |
Didner & Gerge Fonder ABas of 31 Oct 2022 | 2.33m | 4.05% |
Swedbank Robur Fonder ABas of 29 Feb 2024 | 1.69m | 2.94% |
The Vanguard Group, Inc.as of 05 Apr 2024 | 1.14m | 1.98% |
Lancelot Asset Management ABas of 31 Dec 2022 | 625.00k | 1.09% |
SEB Investment Management ABas of 28 Mar 2024 | 621.99k | 1.08% |
E. �hman J :or Fonder ABas of 31 Oct 2022 | 587.94k | 1.02% |
Devon Equity Management Ltd.as of 31 Mar 2024 | 584.48k | 1.01% |
AFA Sjukf�rs�kringsaktiebolag (Invt Mgmt)as of 31 Oct 2022 | 560.46k | 0.97% |
Handelsbanken Fonder ABas of 31 Oct 2022 | 467.69k | 0.81% |